Xconomy | San Diego - Business + Technology in the Exponential Economy

Related Posts

Biotech, diabetes, Life Sciences

Amylin Dissidents Win More Support

Luke Timmerman 5/18/09

Two more firms that advise shareholders on proxy voting—Glass, Lewis & Co. and Proxy Governance—have recommended shareholders of Amylin Pharmaceuticals (NASDAQ: AMLN) throw their support behind dissident directors nominated by Eastbourne Capital and billionaire investor Carl Icahn. Glass Lewis is recommending shareholders vote for three of the five dissidents nominated to the 12-member board, while Proxy Governance is recommending all five dissidents. On Friday, another leading proxy adviser, RiskMetrics Group, recommended dissidents win three seats on the board.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share:   Retweet Facebook Email

Add Your Thoughts



You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted. By clicking "Publish," you are agreeing to these Terms and Conditions.

    
Xconomy network map Seattle Boston San Diego
national life-sciences startups

Most Popular Stories

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.

© 2007-2009, Xconomy, Inc. XCONOMY is a registered service mark of Xconomy, Inc. All rights reserved.
Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.